Trial Profile

Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary) ; Corticosteroid; Pentoxifylline
Indications Alcoholic hepatitis
Focus Therapeutic Use

Most Recent Events

02 Dec 2020 Status changed from not yet recruiting to recruiting as per results published in the Alimentary Pharmacology and Therapeutics.
02 Dec 2020 Results (n=48) assessing microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis, published in the Alimentary Pharmacology and Therapeutics
08 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com